Figure 4
From: Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease
Two-way deterministic sensitivity analyses of select model parameters. (A) DT upfront cost versus yearly discount rate. (B) DT upfront cost versus pediatric QALY weight. (C) Yearly discount rate versus pediatric QALY weight. Parameters were varied simultaneously within their 95% CIs, or ± 20% when unavailable. DT, durable therapy; QALY, quality-adjusted life year; CI, confidence interval; CE, cost-effective; WTP, willingness to pay; K, thousand.
